These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Sandimmun and Neoral treatment: pharmacokinetics and kidney function in paediatric and adolescent renal transplant. De Palma MT; Giordano M; Colella V; Palumbo F; De Nicolo VE; Caringella DA Transplant Proc; 1998 Aug; 30(5):1677. PubMed ID: 9723239 [No Abstract] [Full Text] [Related]
23. Role of postdose cyclosporine monitoring in living renal transplant recipients. Thomas R; Minz M; Singh B; Heer M; Kashyap R Transplant Proc; 2004 Sep; 36(7):2104. PubMed ID: 15518761 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Oellerich M; Armstrong VW; Schütz E; Shaw LM Clin Biochem; 1998 Jul; 31(5):309-16. PubMed ID: 9721427 [No Abstract] [Full Text] [Related]
25. Time-dependent difference of the 12-hour trough levels of cyclosporine in renal transplant recipients with sandimmune capsule. To H; Haba T; Uchida K; Fujimura A; Kobayashi E Transplant Proc; 2000 Feb; 32(1):221-2. PubMed ID: 10701028 [No Abstract] [Full Text] [Related]
26. Cyclosporin C2hour monitoring after renal transplantation. Einecke G; Mai I; Fritsche L; Slowinski T; Waiser J; Glander P; Böhler T; Neumayer HH; Budde K Int J Clin Pharmacol Ther; 2003 Oct; 41(10):477-81. PubMed ID: 14703954 [TBL] [Abstract][Full Text] [Related]
28. Cyclosporine level: which single-point estimation of drug level is the best? Sharma R; Kumar J; Ahmed M; Gupta A; Gulati S; Sharma AP; Bhandari M Transplant Proc; 2001; 33(7-8):3124-5. PubMed ID: 11750343 [No Abstract] [Full Text] [Related]
30. Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazol in stable adult kidney transplants. Foradori A; Mezzano S; Videla C; Pefaur J; Elberg A Transplant Proc; 1998 Aug; 30(5):1685-7. PubMed ID: 9723244 [No Abstract] [Full Text] [Related]
31. C0/C2 cyclosporine levels monitoring in renal transplantation. Santana A; Guerra J; Milhomens C; Neves F; Prata MM Transplant Proc; 2003 May; 35(3):1072-3. PubMed ID: 12947862 [No Abstract] [Full Text] [Related]
32. Optimization of cyclosporine therapy in kidney transplantation. Remuzzi G; Perico N; Gaspari F Transplant Proc; 1998 Aug; 30(5):1673-6. PubMed ID: 9723238 [No Abstract] [Full Text] [Related]
33. Feasibility of changing therapeutic cyclosporine monitoring from C(0) to C(2) in stable renal recipients: narrower coefficient of variation with C(2) monitoring. Chueh SC; Liao CH; Chang CJ; Lai MK Transplant Proc; 2001; 33(7-8):3100-1. PubMed ID: 11750332 [No Abstract] [Full Text] [Related]
34. Neoral drug monitoring in stable kidney allotransplant recipients: C(0) versus C(2). Lukaschek J; Hofmann J; Aerne D; Ambühl P; Kistler T; Knoflach A; Pei P; Binswanger U Transplant Proc; 2001; 33(7-8):3104-5. PubMed ID: 11750334 [No Abstract] [Full Text] [Related]
35. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral. Serafinowicz A; Gaciong Z; Baçzkowska T; Rell K; Lao M; Wałaszewski J Transplant Proc; 1996 Dec; 28(6):3138-9. PubMed ID: 8962216 [No Abstract] [Full Text] [Related]
36. Pharmacokinetics of cyclosporine microemulsion in Pakistani renal allograft recipients: correlation of trough peak levels with 7-point and 3-point AUC. Hussain M; Zafar N; Bux A; Sultan S; Hashmi A; Hussain Z; Hafiz S; Naqvi A; Rizvi A Transplant Proc; 1998 Nov; 30(7):3555. PubMed ID: 9838556 [No Abstract] [Full Text] [Related]
37. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352 [TBL] [Abstract][Full Text] [Related]
38. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method. First MR; Weiskittel P; Burton M; Shah M; Dreyer D; Fleck P; Bey C; Peddi R; Canafax D; Schroeder TJ Transplant Proc; 1998 Aug; 30(5):1701-5. PubMed ID: 9723249 [No Abstract] [Full Text] [Related]
39. Single-center study utilizing C(2) level as monitoring tool in de novo renal transplant recipients treated with Neoral. Keshavamurthy M; Al Ahmadi I; Mohammed Raza S; Baynton R; Al Meshari K; Al Shaibani K Transplant Proc; 2001; 33(7-8):3112-4. PubMed ID: 11750338 [No Abstract] [Full Text] [Related]
40. Comparison of trough level and C(2) cyclosporine blood concentration monitoring in outpatient kidney transplant recipients. Braun F; Armstrong VW; Lorf T; Canelo R; Arndt C; Oellerich M; Ringe B Transplant Proc; 2001; 33(7-8):3108-9. PubMed ID: 11750336 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]